Obstructive Sleep Apnea Market

 Market Overview:

The 7 major obstructive sleep apnea markets reached a value of USD 794.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4,066.7 Million by 2035, exhibiting a growth rate (CAGR) of 16.2% during 2025-2035.

The obstructive sleep apnea market has been comprehensively analyzed in IMARC's new report titled "Obstructive Sleep Apnea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Obstructive sleep apnea refers to a sleep disorder characterized by repetitive interruptions in breathing during sleep. These interruptions, known as apneas, occur when the muscles in the throat fail to keep the airway open, resulting in partial or complete blockage of airflow. The obstruction can lead to a decrease in oxygen levels in the body, causing the patient to briefly wake up or experience shallow sleep-in order to restore normal breathing. The most common symptoms associated with the ailment include loud snoring, excessive daytime sleepiness, gasping or choking during sleep, morning headaches, difficulty concentrating, irritability, restless sleep, etc. The diagnosis of the condition typically involves a thorough evaluation by a healthcare professional specializing in sleep disorders. It begins with a detailed assessment of the patient's medical history, symptoms, and risk factors. The healthcare provider may use questionnaires, such as the Epworth Sleepiness Scale, to assess daytime sleepiness. In many cases, a sleep study, either in a sleep laboratory or through a home-based sleep test, is conducted to confirm the diagnosis.

The rising cases of chronic nasal congestion due to allergies, sinus problems, nasal polyps, etc., which lead to partial or complete blockage of airflow, are primarily driving the obstructive sleep apnea market. Furthermore, the increasing prevalence of several associated risk factors, such as enlarged tonsils or adenoids, obesity, genetic predisposition, use of sedatives, smoking, etc., is also propelling the market growth. Besides this, the widespread adoption of uvulopalatopharyngoplasty for treating the ailment on account of its numerous benefits, including reduced apnea-hypopnea index, improved airflow, decreased cardiovascular risk, etc., is acting as another significant growth-inducing factor. Additionally, the inflating usage of mandibular advancement devices that are custom-made to fit the patient's mouth and work by repositioning the jaw to help keep the airway open during sleep is further bolstering the market growth. Apart from this, the escalating demand for hypoglossal nerve stimulation (HNS), which involves implanting a device to stimulate the hypoglossal nerve that controls tongue movement and other muscles involved in maintaining airway patency for improved breathing during sleep, is expected to drive the obstructive sleep apnea market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the obstructive sleep apnea market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for obstructive sleep apnea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obstructive sleep apnea market in any manner.

Recent Developments:

• In December 2024, the US Food and Drug Administration announced the approval of Zepbound (Tirzepatide) as the first medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This treatment is intended to be used alongside a reduced-calorie diet and increased physical  activity. 
• In May 2024, Incannex Healthcare Inc. announced that patient dosing had commenced in the Company’s Phase 2/3 clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea .
• In April 2024, Eli Lilly announced favorable top-line outcomes from the SURMOUNT-OSA phase 3 clinical trials. These results revealed that tirzepatide injection (at either 10 mg or 15 mg) significantly lowered the apnea-hypopnea index (AHI) in comparison to the placebo, successfully fulfilling the primary objectives.
• In March 2024, Desitin disclosed encouraging outcomes from the FLOW study, encompassing 298 patients, which demonstrated a noteworthy decrease in nocturnal breathing pauses among those with obstructive sleep apnea (OSA), effectively meeting the primary endpoint of the study.
• In January 2024, Incannex announced it had secured IRB approval for the RePOSA Phase 2/3 Clinical Trial Protocol, marking a significant milestone in their efforts to assess the efficacy and safety of the IHL-42X drug in patients with OSA, potentially paving the way for new treatment options in this condition.

Key Highlights:

• Obstructive sleep apnea is widespread among middle-aged and elderly people.
• Obstructive sleep apnea affects around one out of every fifty children.
• It is also more prevalent in men than women.
• The estimated frequency in North America is roughly 15-30% in males and 10-15% in females.
• Obstructive sleep apnea is expected to impact 1-3% of non-obese, otherwise healthy children under the age of eight.

Drugs:

Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea. It is not a treatment for the underlying airway obstruction in apnea patients. Solriamfetol hydrochloride is a white to off-white solid that is freely soluble in water. SUNOSI tablets are intended for oral administration.

Armodafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.)

Retatrutide is an investigational treatment being developed for obstructive sleep apnea (OSA) and obesity. It is characterized by its unique composition as a single peptide conjugated to a fatty diacid moiety. This conjugation enhances its pharmacokinetic properties and allows for sustained activity within the body. Retatrutide exhibits agonistic effects toward multiple receptors, including the glucose-dependent insulinotropic polypeptide (GIP), the glucagon-like peptide-1 (GLP-1), and the glucagon (GCG) receptors.

AD109 is a first-in-class, innovative, experimental combination that is administered once daily at bedtime and is intended to treat obstructive sleep apnea patients with a wide range of disease severity. AD109 combines Apnimed's innovative selective antimuscarinic (aroxybutynin) and atomoxetine, a selective norepinephrine reuptake inhibitor. AD109 affects important neurological pathways in obstructive sleep apnea, activating upper airway dilator muscles to maintain an open airway during sleep.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the obstructive sleep apnea market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the obstructive sleep apnea market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current obstructive sleep apnea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the obstructive sleep apnea market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the obstructive sleep apnea market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the obstructive sleep apnea market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of obstructive sleep apnea across the seven major markets?
• What is the number of prevalent cases (2019-2035) of obstructive sleep apnea by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of obstructive sleep apnea by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with obstructive sleep apnea across the seven major markets?
• What is the size of the obstructive sleep apnea patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of obstructive sleep apnea?
• What will be the growth rate of patients across the seven major markets?
   

Obstructive Sleep Apnea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for obstructive sleep apnea drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obstructive sleep apnea market?
• What are the key regulatory events related to the obstructive sleep apnea market?
• What is the structure of clinical trial landscape by status related to the obstructive sleep apnea market?
• What is the structure of clinical trial landscape by phase related to the obstructive sleep apnea market?
• What is the structure of clinical trial landscape by route of administration related to the obstructive sleep apnea market?